(AOF) – Boiron, the homeopathy specialist, recorded a turnover up 35.2% for the first half of 2022, to 256.762 million euros. Growth was 25.2% in France and 47.6% internationally. Net profit – group share amounted to 12.52 million euros. Sales of new products launched since 2020 amounted to approximately 47 million euros, compared to 15 million euros in the first half of 2021.
In terms of outlook, the group expects an increase in turnover in all geographical areas as well as a significant change in profitability.
“In a context of sustained inflation and tension on certain energy and raw material supplies, we are doing everything we can to ensure the availability of our medicines and our entire range of products. We are also remaining vigilant on the evolution of the global health crisis, and continue to take appropriate measures whenever necessary”, specifies the management of Boiron.